Author + information
- Received August 18, 2006
- Revision received September 19, 2006
- Accepted November 19, 2006
- Published online April 10, 2007.
- Nobuhiro Tahara, MD, PhD⁎,⁎ (, )
- Hisashi Kai, MD, PhD⁎,
- Sho-ichi Yamagishi, MD, PhD⁎,
- Minori Mizoguchi, MD⁎,
- Hiroyuki Nakaura, MD, PhD⁎,
- Masatoshi Ishibashi, MD, PhD†,
- Hayato Kaida, MD, PhD†,
- Kenkichi Baba, MD†,
- Naofumi Hayabuchi, MD, PhD† and
- Tsutomu Imaizumi, MD, PhD⁎
- ↵⁎Reprints requests and correspondence:
Dr. Nobuhiro Tahara, Department of Medicine, Division of Cardio-Vascular Medicine, Kurume University School of Medicine, 67 Asahimachi, Kurume 830-0011, Japan.
Objectives We investigated factors for carotid artery inflammation by [18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET).
Background Inflammation is present in some atherosclerotic plaques. The FDG-PET is capable of identifying and quantifying vascular inflammation within atherosclerotic plaques.
Methods The FDG-PET imaging was performed in 216 consecutive patients (63 ± 9 years, men:women 147:69) for cancer screening. Vascular inflammation in carotid atherosclerosis was quantified by measuring the standardized uptake value (SUV) of FDG into the artery.
Results Multiple stepwise regression analysis revealed significant relationships between SUV and waist circumference (p < 0.001), hypertensive medication (p < 0.001), carotid intima-media thickness (p < 0.001), high-density lipoprotein cholesterol (p < 0.01, inversely), homeostasis model assessment of insulin resistance (p < 0.05), or high sensitivity C-reactive protein (p < 0.05). Age- and gender-adjusted SUV of FDG was significantly higher (p < 0.0001) in proportion to the accumulation of the number of the components of the metabolic syndrome. Thus, the metabolic syndrome was associated with increased FDG uptake in carotid atherosclerosis.
This study was supported, in part, by a research grant from the Kimura Memorial Foundation to Dr. Imaizumi; by a grant from the Ishibashi Foundation for the Promotion of Science to Dr. Tahara; by a grant from Fukuda Foundation for Medical Technology to Dr. Tahara; by a grant from Mitsui Life Social Welfare Foundation to Dr. Tahara; and by a grant for the Academic Frontier Project from the Ministry of Education, Science, Sports, Culture, and Technology, Japan (Cardiovascular Research Institute, Kurume University).
- Received August 18, 2006.
- Revision received September 19, 2006.
- Accepted November 19, 2006.
- American College of Cardiology Foundation